Matinas BioPharma Holdings (MTNB) Share-based Compensation (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Share-based Compensation of $113000.0 for Q1 2026, down 64.13% year-over-year from $315000.0 in Q1 2025, and down 47.93% quarter-over-quarter from $217000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Share-based Compensation (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Share-based Compensation for 14 consecutive years, with $113000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 64.13% year-over-year to $113000.0; the TTM figure through Mar 2026 stood at $821000.0 (down 67.36% YoY), while the FY2025 annual figure was $1.0 million, down 67.98% from the prior year.
- Share-based Compensation declined to $113000.0 in Q1 2026 per MTNB's latest filing, from $217000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.4 million in Q3 2022 and bottomed at $113000.0 in Q1 2026.
- Historically, Share-based Compensation has averaged $853352.9 across 5 years, with a median of $995000.0 in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 33.18% — and 2024, when it tumbled 80.82%.
- Matinas BioPharma Holdings' Share-based Compensation stood at $1.3 million in 2022, then fell by 5.07% to $1.3 million in 2023, then sank by 80.82% to $244000.0 in 2024, then fell by 11.07% to $217000.0 in 2025, then sank by 47.93% to $113000.0 in 2026.
- Business Quant data shows MTNB's Share-based Compensation at $113000.0 in Q1 2026, $217000.0 in Q4 2025, and $253000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 391,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 391,000.00 |
| Jun 30, 2026 | 391,000.00 |
| Mar 31, 2026 | 113,000.00 |
| Mar 31, 2026 | 113,000.00 |
| Dec 31, 2025 | 217,000.00 |
| Dec 31, 2025 | 217,000.00 |
| Sep 30, 2025 | 253,000.00 |
| Sep 30, 2025 | 253,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Dec 31, 2024 | 244,000.00 |
| Dec 31, 2024 | 244,000.00 |
| Sep 30, 2024 | 965,000.00 |
| Sep 30, 2024 | 965,000.00 |
| Jun 30, 2024 | 991,000.00 |
| Jun 30, 2024 | 991,000.00 |
| Mar 31, 2024 | 995,000.00 |
| Mar 31, 2024 | 995,000.00 |